Phase 2 Clinical Trial Data Show Significant Improvements in Outcomes and Symptoms in Advanced Heart Failure Patients Treated with Celladon's Genetically Targeted Enzyme Replacement Therapy MYDICAR®
Advertisement
CUPID Trial Data Presented Today as Late-Breaker at Heart Failure 2010, the Annual Meeting of the Heart Failure Association of the European Society of Cardiology